Revolution Medicines has set the list price of its newly approved pancreatic cancer pill at about $39,800 for a 30-day supply, which works out to roughly $477,600 for twelve consecutive fills. The company disclosed the figure in a securities filing and on the investor call it held the day the drug was approved. Taken as two tablets once daily, that comes to about $663 a tablet, as reported by The New York Times.
For families weighing this treatment, the sticker price is not the number that matters most. What a household actually pays depends almost entirely on the type of insurance it carries. A Medicare beneficiary and a commercially insured patient with a high deductible can fill the identical prescription in January and face very different bills.
The Sticker Price and What Patients Actually Pay
Rasonque, known generically as daraxonrasib, was cleared for previously treated metastatic pancreatic adenocarcinoma in adults who have had at least one prior systemic therapy or who cannot take multiagent chemotherapy. The FDA granted the approval roughly six and a half months ahead of its user fee deadline, under a pilot program meant to speed reviews of treatments addressing national health priorities.
The wholesale acquisition cost is a list price before rebates, and few payers pay it. The company set the wholesale acquisition cost at that level while saying eligible commercially insured patients may pay nothing out of pocket through copay assistance. A company spokesperson has said uninsured and underinsured patients who meet financial and medical criteria will receive the drug free. Executives also told investors they expect government discounts and rebates to reduce the effective price by an estimated 20% to 30%.
Those programs are real and conditional. Eligibility rules, income thresholds and annual caps vary, and manufacturer copay assistance is generally unavailable to patients on Medicare or Medicaid under federal anti-kickback rules.
Medicare's Cap Changes the Math for Older Adults
Pancreatic cancer is diagnosed disproportionately in older adults, so many patients taking this drug will be on Medicare.
The Inflation Reduction Act created an annual out-of-pocket cap on Part D drugs, set at $2,100 this year and rising to $2,400 in 2027. Because Rasonque is a pharmacy-dispensed tablet rather than an infused therapy, it falls under Part D, and the cap applies. Cancer is a protected class under Part D, which generally obligates plans to cover drugs in the category, though prior authorization and cost sharing still apply and rules differ across plans.
Vanderbilt health policy professor Stacie Dusetzina, who studies drug pricing, calculated that without that cap many Medicare patients would have faced more than $25,000 a year for this single prescription. She has also noted that the price question is harder than usual here, saying the drug does have substantial clinical benefits over existing treatment. Medicare beneficiaries can additionally spread their out-of-pocket costs across the year rather than absorbing one large charge.
Commercial Plans and the January Deductible Problem
Patients with employer or marketplace coverage face a different structure and a specific vulnerability. Commercial plans reset deductibles on January 1. A patient filling the first prescription of the year against an unmet deductible can face a very large single charge, even though annual out-of-pocket maximums eventually cap total exposure.
Dr. Aaron Kesselheim, a Harvard professor of medicine at Brigham and Women's Hospital who studies drug pricing, has argued the underlying problem is structural, saying the country allows pharmaceutical companies to charge whatever they want.
Practical steps exist. Patients can ask the oncologist's office about the manufacturer's assistance program before the first fill, confirm prior authorization requirements, and ask whether the insurer's required specialty pharmacy can supply the drug on schedule. Independent nonprofit foundations also help with cancer drug costs, though their funds open and close episodically.
Value, Precedent and the Questions Still Open
The clinical case is unusually strong, which is why the price is drawing scrutiny rather than reflexive criticism. In the 500-patient RASolute 302 trial, median overall survival was 13.2 months on daraxonrasib against 6.7 months on chemotherapy, a hazard ratio of 0.40 that amounts to a 60% reduction in the risk of death. Results presented at the ASCO annual meeting drew a standing ovation and were published simultaneously in the New England Journal of Medicine. Angelo de Claro, director of the FDA's Oncology Center of Excellence, said the drug showed unprecedented results in an area of high unmet need.
Much of the historical anger over cancer drug pricing has targeted medicines that shrank tumors without proving they extended lives. This one extended lives in a randomized trial.
Health economist Joshua Cohen, writing in Forbes, argues the price still raises questions about long-term sustainability, since every high-cost approval draws on the same insurance pools and public budgets.
Several things remain unsettled. Net prices after rebates are confidential. Two of the largest pharmacy benefit managers have said they are still reviewing the drug, and it is unclear how commercial plans will handle prior authorization or whether they will limit coverage strictly to the trial criteria. The drug is taken until disease progression or unacceptable toxicity, so duration and total spending vary widely. In the pivotal trial, the median time on treatment was about six months.
Patients should not make treatment decisions based on list prices. Anyone whose oncologist raises this drug should ask what their own plan requires and what assistance they qualify for before assuming the cost is out of reach.
Key Questions Answered
What does Rasonque cost? The list price is about $39,800 for a 30-day supply, roughly $477,600 for twelve fills. That is before insurance, rebates, or assistance.
Will Medicare cover it? Cancer drugs are a protected class under Part D, and the annual out-of-pocket cap applies. That cap is $2,100 this year and $2,400 in 2027.
What about commercial insurance? Coverage varies. The main risk is a January deductible reset producing a very large first bill.
Is help available for uninsured patients? The manufacturer says uninsured and underinsured patients meeting financial and medical criteria will receive the drug free.
Who is eligible? Adults with metastatic pancreatic adenocarcinoma who have had a prior systemic therapy or cannot take multiagent chemotherapy. Earlier-stage disease is not covered.
How long do patients take it? Until the disease progresses or side effects become unacceptable. In the pivotal trial, the median was about six months.
Is it a cure? No. It extended median survival from 6.7 to 13.2 months and does not eliminate the disease.
